Savara has received a development award of up to $5 million from Cystic Fibrosis Foundation Therapeutics (CFFT), which will support the Phase 3 AVAIL study of the AeroVanc DPI for the treatment of MRSA lung infections in cystic fibrosis patients, the company said. In 2013, CFFT awarded the company $1.7 million for Phase 2 development of AeroVanc.
Savara announced the initiation of the AVAIL study in September 2017. The study is expected to enroll 200 CF patients in the US and Canada.
Savara CEO Rob Neville said, “We are delighted to have the CF Foundation’s continued support and we believe this award serves as strong validation of our AeroVanc program. Our AVAIL study was planned in consultation with the CF Foundation’s Therapeutic Development Network as well as key opinion leaders (KOL’s) across the country, and we are excited to have the study started and enrolling.”
Read the Savara press release.
